RYDER SYSTEM, INC. $• •% [Debentures][Notes] due • Form of Underwriting Agreement
Exhibit 1.1
RYDER
SYSTEM, INC.
$•
•% [Debentures][Notes] due
•
Form of Underwriting Agreement
To the Representatives
named in Schedule I
hereto of the Underwriters
named in Schedule II hereto
named in Schedule I
hereto of the Underwriters
named in Schedule II hereto
Dear Sirs:
Ryder System, Inc., a Florida corporation (the “Company”), confirms its agreement with each of
the Underwriters named in Schedule II hereto (collectively, the “Underwriters,” which term shall
also include any underwriter substituted as hereinafter provided in Section 9 hereof), for whom the
representative or representatives, if any, named in Schedule I hereto are acting as representatives
(in such capacity, the “Representatives”), with respect to the issue and sale by the Company and
the purchase by the Underwriters, acting severally and not jointly, of the respective principal
amounts set forth in said Schedule II of the securities identified in Schedule I hereto (the
“Securities”). The Securities are to be issued pursuant to an indenture, dated as of October 3,
2003, (as amended and supplemented, the “Indenture”), between the Company and The Bank of New York
Mellon Trust Company, N.A. as successor to X.X. Xxxxxx Trust Company, National Association, as
trustee (the “Trustee”). If the firm or firms listed in Schedule II hereto include only the firm
or firms listed in Schedule I hereto, then the terms “Underwriters” and “Representatives,” as used
herein, shall each be deemed to refer to such firm or firms. The term “Representatives” also
refers to a single firm acting as sole representative of the Underwriters. Certain terms used
herein are defined in Section 17 hereof.
On February 25, 2010, the Company filed with the Commission an automatic shelf registration
statement on Form S-3 (No. 333-xxxxx) (as filed on such date, the “Original Registration
Statement”) including the related base prospectus (the “Base Prospectus”), which registration
statement became effective upon filing under Rule 462(e). Such registration statement covers the
registration of the Securities under the Act. Such registration statement, in the form in which it
became effective, including the exhibits and any schedules thereto including any required
information deemed to be a part thereof at the time of effectiveness pursuant to Rule 430B under
the Act, is herein called the “Registration Statement.” The Company has filed or will file with
the Commission pursuant to the applicable paragraph of Rule 424(b) under the Act, a supplement to
the Base Prospectus relating to the Securities and the plan of distribution thereof (the
“Prospectus Supplement”). The term “Prospectus” shall mean the final prospectus supplement
relating to the Securities, together with the Base Prospectus, that is first filed pursuant to
Rule 424(b) under the Act after the date and time that this Agreement is executed (the “Execution
Time”) by the parties hereto. The term “Preliminary Prospectus” shall mean any
preliminary prospectus supplement relating to the Securities, together with the Base
Prospectus, that is first filed with the Commission pursuant to Rule 424(b) under the Act. Any
reference herein to the Registration Statement, the Base Prospectus, the Preliminary Prospectus or
the Prospectus shall be deemed to refer to and include the documents incorporated by reference
therein pursuant to Item 12 of Form S-3 which were filed under the Exchange Act on or before the
effective date of the Registration Statement or the issue date of the Base Prospectus, the
Preliminary Prospectus or the Prospectus, as the case may be; and any reference herein to the terms
“amend”, “amendment” or “supplement” with respect to the Registration Statement, the Base
Prospectus, the Preliminary Prospectus or the Prospectus shall be deemed to refer to and include
the filing of any document under the Exchange Act after the Effective Date of the Registration
Statement or the issue date of the Basic Prospectus, the Preliminary Prospectus or the Prospectus,
as the case may be, deemed to be incorporated therein by reference.
1. Representations and Warranties. The Company represents and warrants to each
Underwriter as of the date hereof, the Time of Sale and as of the Closing Date referred to in
Section 3 hereof (each of the times referenced above being referred to herein as a “Representation
Date”), and agrees with each Underwriter, as follows
(a) (i)(A) At the time of filing the Original Registration Statement, (B) at the time of the
most recent amendment thereto for the purposes of complying with Section 10(a)(3) of the Act
(whether such amendment was by post-effective amendment, incorporated report filed pursuant to
Section 13 or 15(d) of the Exchange Act or form of prospectus), (C) at the time the Company or any
person acting on its behalf (within the meaning, for this clause only, of Rule 163(c)) made any
offer relating to the Securities in reliance on the exemption of Rule 163 and (D) at the date
hereof, the Company was and is a “well-known seasoned issuer” as defined in Rule 405. The
Registration Statement is an “automatic shelf registration statement,” as defined in Rule 405. The
Company has not received from the Commission any notice pursuant to Rule 401(g)(2) objecting to the
use of the automatic shelf registration statement form.
(ii) At the time of filing the Original Registration Statement, at the earliest time
thereafter that the Company or another offering participant made a bona fide offer (within
the meaning of Rule 164(h)(2)) of the Securities and at the date hereof, the Company was not
and is not an “ineligible issuer,” as defined in Rule 405.
(iii) The Original Registration Statement became effective upon filing under Rule 462(e)
on February 25, 2010, and any post-effective amendment thereto also became effective upon
filing under Rule 462(e). The Original Registration Statement was filed with the Commission
not earlier than three years prior to the applicable Representation Date. No stop order
suspending the effectiveness of the Registration Statement has been issued under the Act and
no proceedings for that purpose have been instituted or are pending or, to the knowledge of
the Company, are contemplated by the Commission, and any request on the part of the
Commission for additional information has been complied with.
2
(b) (i) As of the Execution Time, the Effective Date, the date any supplement to the
Prospectus is filed with the Commission, the date of any pricing term sheet relating to the
sale of Securities and the date of delivery by the Company of any Securities sold hereunder
(a “Closing Date”), (i) the Registration Statement, as amended as of any such time, and the
Prospectus, as supplemented as of any such time, and the Indenture complied and will comply
in all material respects with the applicable requirements of the Act, the Trust Indenture
Act and the Exchange Act and the respective rules thereunder; (ii) the Registration
Statement, as amended as of any such time, did not and will not contain any untrue statement
of a material fact or omit to state any material fact required to be stated therein or
necessary in order to make the statements therein not misleading; and (iii) the Prospectus,
as supplemented as of any such time, did not and will not contain any untrue statement of a
material fact or omit to state a material fact necessary in order to make the statements
therein, in the light of the circumstances under which they were made, not misleading;
provided, however, that the Company makes no representations or warranties
as to (i) that part of the Registration Statement which shall constitute the Statement of
Eligibility (Form T-1) under the Trust Indenture Act of the Trustee or (ii) the information
contained in or omitted from the Registration Statement or the Prospectus (or any supplement
thereto) in reliance upon and in conformity with information furnished in writing to the
Company by or on behalf of any or all of you specifically for use in connection with the
preparation of the Registration Statement or the Prospectus (or any supplement thereto).
(ii) As of the Time of Sale, the Time of Sale Prospectus (i) will conform in all
material respects to the requirements of the Act and the rules and
regulations thereunder and (ii) did not contain an untrue
statement of a material fact or omit to state a material fact necessary in order to make the
statements therein, in the light of the circumstances under which they were made, not
misleading.
(iii) The Company (including its agents and representatives) has not made, used,
prepared, authorized, approved or referred to and will not prepare, make, use, authorize,
approve or refer to or make any offer relating to the Securities that would constitute a
Free Writing Prospectus (as defined in Rule 405 under the Act) other than (i) any document
not constituting a prospectus pursuant to Section 2(a)(10)(a) of the Act; or (ii) other
written communications approved in writing in advance by the Representatives including any
pricing term sheet. To the extent required pursuant to Rule 433(d) under the Act, any such
Free Writing Prospectus as of its issue date and at all subsequent times through the
completion of the public offer and sale of the Securities, complies or will comply in all
material respects with the requirements of the Act and has been, or will be, filed with the
Commission in accordance with the Act (to the extent required pursuant to Rule 433(d) under
the Act).
(iv) Each Issuer Free Writing Prospectus as of its issue date and at all subsequent
times through the completion of the public offer and sale of the particular Securities, did
not, does not and will not include any information that conflicted, conflicts
3
or will conflict (within the meaning of Rule 433(c)) under the Act with the information
then contained in the Registration Statement, any applicable Preliminary Prospectus or the
Prospectus; and each such Issuer Free Writing Prospectus, as supplemented by and taken
together with the Time of Sale Prospectus as of the Time of Sale, did not, does not and will
not include any untrue statement of a material fact or omit to state any material fact
necessary in order to make the statements therein, in the light of the circumstances under
which they were made, not misleading. The preceding sentence shall not apply to statements
in or omissions from any Issuer Free Writing Prospectus in reliance upon and in conformity
with information furnished in writing to the Company by or on behalf of any or all of you
specifically for use in connection with the preparation of the Issue Free Writing
Prospectus.
The representations and warranties in this subsection (b) shall not apply to statements in or
omissions from the Registration Statement, the Prospectus, the Time of Sale Prospectus or any
Issuer Free Writing Prospectus made in reliance upon and in conformity with written information
furnished to the Company by any Agent through the Representatives expressly for use therein.
(c) The documents incorporated by reference into (i) the Registration Statement, (ii) the
Prospectus or (iii) the Time of Sale Prospectus, when they were filed with the Commission conformed
in all material respects to the requirements of the Exchange Act and none of such documents, when
they were so filed, contained any untrue statement of a material fact or omitted to state a
material fact required to be stated therein or necessary to make the statements therein, in the
light of the circumstances under which they were made, not misleading; and any further documents so
filed and incorporated by reference in the Registration Statement, the Prospectus or the Time of
Sale Prospectus, when such documents become effective or are filed with the Commission, as the case
may be, will conform in all material respects to the requirements of the Act or the Exchange Act,
as applicable, and will not contain any untrue statement of a material fact or omit to state a
material fact required to be stated therein or necessary to make the statements therein, in the
light of the circumstances under which they were made, not misleading.
(d) The Company consents to the use by any of the Agents of a Free Writing Prospectus that (a)
is not an Issuer Free Writing Prospectus (as defined in Rule 433 under the Act), and (b) contains
only (i) information describing the preliminary terms of the Securities or their offering, (ii)
information permitted by Rule 134 under the Act or (iii) information that describes the final terms
of the Securities or their offering and that is included in the relevant pricing term sheet.
(e) The Company has not distributed and will not distribute, prior to the later of the
settlement date and the completion of the Representatives’ distribution of the Securities, any
offering material in connection with the offering and sale of the Securities other than the
Prospectus, or any Issuer Free Writing Prospectus reviewed and consented to by the Representatives
or included in the Registration Statement.
4
(f) The Company and each of its subsidiaries that constitutes a “significant subsidiary” (as
such term is defined in Rule 1-02 of Regulation S-X) (collectively, the “Significant Subsidiaries”)
has been duly organized and is a validly existing entity in good standing under the laws of the
jurisdiction of its organization, with corporate or limited liability company power, as applicable,
and authority to own its properties and conduct its business as described in the Registration
Statement, the Time of Sale Prospectus and the Prospectus, and has been duly qualified as a foreign
corporation or limited liability company, as applicable, for the transaction of business and is in
good standing under the laws of each other jurisdiction in which it owns or leases properties,
except where the failure, individually or in the aggregate, to so qualify would not reasonably be
expected to have a material adverse effect on the business, results of operations or financial
condition of the Company and its subsidiaries taken as a whole (a “Material Adverse Effect”).
(g) All the outstanding shares of capital stock of each Significant Subsidiary have been duly
authorized and validly issued and are fully paid and non-assessable, and, except as otherwise set
forth in the Registration Statement, the Time of Sale Prospectus and the Prospectus, all
outstanding shares of capital stock of the Significant Subsidiaries are owned by the Company either
directly or through wholly owned subsidiaries free and clear of any security interest, claim, lien
or encumbrance, other than any such security interests, claims, liens or encumbrances which would
not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.
(h) This Agreement has been duly authorized, executed and delivered by the Company.
(i) The Indenture has been duly qualified under the Trust Indenture Act and has been duly
authorized, executed and delivered by the Company and constitutes a valid and binding agreement of
the Company, enforceable in accordance with its terms (except as the enforceability thereof may be
limited by bankruptcy, insolvency and other laws affecting the enforceability of creditors’ rights
generally and general principles of equity and an implied covenant of
good faith and fair dealing); and the Indenture conforms in all
material respects to the descriptions thereof in the Time of Sale
Prospectus and the Prospectus.
(j) The Securities have been duly authorized by the Company and, when executed and
authenticated in accordance with the terms of the Indenture and delivered to and paid for by the
Underwriters in accordance with the terms of this Agreement, will have been duly executed and
delivered by the Company, and will constitute valid and binding obligations of the Company entitled
to the benefits of the Indenture and enforceable in accordance with their terms and the terms of
the Indenture (except as the enforceability thereof may be limited by bankruptcy, insolvency and
other laws affecting the enforceability of creditors’ rights generally and general principles of
equity and an implied covenant of good faith and fair dealing); and the Securities and the
Indenture conform in all material respects to the descriptions thereof in the Time of Sale
Prospectus and the Prospectus.
5
(k) Neither the execution and delivery of this Agreement, the Indenture, the issue and sale of
the Securities, nor the consummation of any other of the transactions herein contemplated nor the
fulfillment of the terms hereof will conflict with, result in a breach of, or constitute a default
under (i) the charter or by-laws of the Company, (ii) the terms of any indenture or other agreement
or instrument to which the Company or any of its subsidiaries is a party or bound, or (iii) any
law, statute, order or regulation applicable to the Company or any of its subsidiaries of any
court, regulatory body, administrative agency, governmental body or arbitrator having jurisdiction
over the Company or any of its subsidiaries, or any of their assets, properties or operations,
except, with respect to (ii) and (iii) above, for any such violations that would not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect.
(l) No consent, approval, authorization, order, registration or qualification of or with any
court or governmental agency or body is required for the due authorization, execution and delivery
by the Company of this Agreement or for the performance by the Company of the transactions
contemplated under the Time of Sale Prospectus and the Prospectus, this Agreement or the Indenture,
except such as have already been made, obtained or rendered, as applicable, and such as may be
required under state securities laws.
(m) The Company and its subsidiaries maintain an effective system of “disclosure controls and
procedures” (as defined in Rule 13a-15(e) under the Exchange Act) that is designed to ensure that
information required to be disclosed by the Company in reports that it files or submits under the
Exchange Act is recorded, processed, summarized and reported within the time periods specified in
the Commission’s rules and forms, including controls and procedures designed to ensure that such
information is accumulated and communicated to the Company’s management as appropriate to allow
timely decisions regarding required disclosure. The Company and its subsidiaries have carried out
evaluations of the effectiveness of their disclosure controls and procedures as required by Rule
13a-15 under the Exchange Act.
(n) Except as disclosed in the Registration Statement, the Time of Sale Prospectus and the
Prospectus or in any document incorporated by reference therein, since the end of the Company’s
most recently audited fiscal year there has been (i) no material weakness in the Company’s internal
control over financial reporting (whether or not remediated) and (ii) no change in the Company’s
internal control over financial reporting that has materially affected, or is reasonably likely to
materially affect, the Company’s internal control over financial reporting. Since the date of the
most recently available audited financial statements, the Company and its subsidiaries have
maintained effective internal control over financial reporting, as such term is defined in Rule
13a-15(f) under the Exchange Act.
(o) The financial statements and schedules of the Company and its consolidated subsidiaries
included or incorporated by reference in the Registration Statement, the Time of Sale Prospectus
and the Prospectus present fairly in all material respects the consolidated financial condition,
results of operations and cash flows of the Company and its consolidated subsidiaries as of the
dates and for the periods indicated, comply as to form with the
6
applicable accounting requirements of the Act or the Exchange Act, as applicable, and have
been prepared in conformance with United States generally accepted accounting principles applied on
a consistent basis throughout the periods involved (except as otherwise noted therein).
(p) The Company’s registered independent public accountants, who have certified certain
financial statements of the Company and its subsidiaries, is an independent registered public
accounting firm with respect to the Company and its subsidiaries within the applicable rules and
regulations adopted by the Commission and the Public Accounting Oversight Board (United States) and
as required by the Act.
(q) The Company is not and, after giving effect to the offering and sale of the Securities and
the application of the proceeds thereof as described in the Prospectus and the Time of Sale
Prospectus, will not be an “investment company” as defined in the Investment Company Act.
(r) Except as described in the Registration Statement, the Time of Sale Prospectus and the
Prospectus, there are no legal or governmental proceedings pending to which the Company or any of
its Significant Subsidiaries is a party or to which any property of the Company or any of its
Significant Subsidiaries is subject other than litigation or other proceedings which would not,
individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and, to
the knowledge of the Company’s officers, no such proceedings are threatened or contemplated by
governmental authorities.
(s) The Company will not directly or indirectly use the proceeds of the offering, or lend,
contribute or otherwise make available such proceeds in any manner that would violate the Trading
With the Enemy Act (50 U.S.C. § 1 et seq., as amended) (the “Trading With the Enemy Act”) or any of
the foreign assets control regulations of the United States Treasury Department (31 CFR, Subtitle
B, Chapter V, as amended) (the “Foreign Assets Control Regulations”) or any enabling legislation or
executive order relating thereto (which for the avoidance of doubt shall include, but shall not be
limited to (a) Executive Order 13224 of September 21, 2001 Blocking Property and Prohibiting
Transactions With Persons Who Commit, Threaten to Commit, or Support Terrorism (66 Fed. Reg. 49079
(2001)) (the “Executive Order”) and (b) the Uniting and Strengthening America by Providing
Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (Public Law 107-56)).
Furthermore, neither the Company nor any of its subsidiaries (a) is a “blocked person” as described
in the Executive Order, the Trading With the Enemy Act or the Foreign Assets Control Regulations or
(b) engages in any dealings or transactions, or be otherwise associated, with any such “blocked
person”.
7
2. Purchase and Sale. Subject to the terms and conditions and in reliance upon the
representations and warranties herein set forth, the Company agrees to sell to each Underwriter,
and each Underwriter agrees, severally and not jointly, to purchase from the Company, at the
purchase price set forth in Schedule I hereto, the amount of the Securities set forth opposite such
Underwriter’s name in Schedule II hereto.
3. Delivery and Payment. Delivery of and payment for the Securities shall be made on
the date and at the time specified in Schedule I hereto or at such time on such later date not more
than three Business Days after the foregoing date as the Representatives shall designate, which
date and time may be postponed by agreement between the Representatives and the Company or as
provided in Section 9 hereof (such date and time of delivery and payment for the Securities being
herein called the “Closing Date”). Delivery of the Securities shall be made to the Representatives
for the respective accounts of the several Underwriters against payment by the several Underwriters
through the Representatives of the purchase price thereof to or upon the order of the Company by
wire transfer payable in same-day funds to an account specified by the Company. Delivery of the
Securities shall be made through the facilities of The Depository Trust Company unless the
Representatives shall otherwise instruct.
4. Offering by Underwriters. It is understood that the several Underwriters propose
to offer the Securities for sale to the public as set forth in the Time of Sale Prospectus.
5. Agreements. The Company agrees with the several Underwriters that:
(a) Prior to the termination of the offering of the Securities, the Company will not file any
amendment of the Registration Statement or any supplement or amendment to either any preliminary
prospectus or to the Prospectus, whether pursuant to the Act, the Exchange Act or otherwise unless
the Company has furnished you a copy for your review prior to filing and will not file any such
proposed amendment or supplement to which you reasonably object. The Company will prepare a final
term sheet (the “Final Term Sheet”), in substantially the form of Exhibit A hereto, reflecting the
final terms of the Securities, in form and substance satisfactory to the Representatives, and shall
file such Final Term Sheet as an “issuer free writing prospectus” pursuant to Rule 433 prior to the
close of business two Business Days after the date hereof; provided that the Company shall furnish
the Representatives with copies of any such Final Term Sheet a reasonable amount of time prior to
such proposed filing and will not use or file any such document to which the Representatives or
counsel to the Underwriters shall object. Subject to the second preceding sentence, the Company
will comply with the requirements of Rule 430B and cause the Prospectus, properly completed, and
any supplement thereto to be filed in a form approved by the Representatives with the Commission
pursuant to the applicable paragraph of Rule 424(b) within the time period prescribed (without
reliance on Rule 424(b)(8)), and will provide evidence satisfactory to the Representatives of such
timely filing. The Company will promptly advise the Representatives (1) when any post-effective
amendment to the Registration Statement or new registration statement relating to the Securities
shall become effective, (2) when the Prospectus, and any supplement thereto, shall have been filed
(if required) with the Commission pursuant to Rule 424(b), (3) of the receipt of any comments from
the Commission,
8
(4) of any request by the Commission or its staff for any amendment of the Registration
Statement, or for any supplement to the Prospectus or any document incorporated by reference
therein or otherwise deemed to be a part thereof, or for any additional information, (5) of the
issuance by the Commission of any stop order suspending the effectiveness of the Registration
Statement or the institution or threatening of any proceeding for that purpose or any notice
pursuant to Rule 401(g)(2) of the Regulations or any order preventing or suspending the use of any
preliminary prospectus, or of the initiation or threatening of any proceedings for any of such
purposes or of any examination pursuant to Section 8(e) of the Act concerning the Registration
Statement, (6) if the Company becomes the subject of a proceeding under Section 8A of the Act in
connection with the offering of the Securities and (7) of the receipt by the Company of any
notification with respect to the suspension of the qualification of the Securities for sale in any
jurisdiction or the institution or threatening of any proceeding for such purpose. The Company
will use its best efforts to prevent the issuance of any such stop order or the suspension of any
such qualification and, if issued, to obtain as soon as possible the withdrawal thereof. The
Company shall pay the required Commission filing fees relating to the Securities within the time
required by Rule 456(b)(1) (i) of the Regulations without regard to the proviso therein and
otherwise in accordance with Rules 456(b) and 457(r) of the Regulations (including, if applicable,
by updating the “Calculation of Registration Fee” table in accordance with Rule 456(b)(1)(ii)
either in a post-effective amendment to the Registration Statement or on the cover page of a
prospectus filed pursuant to Rule 424(b)).
(b) If, at any time when a prospectus relating to the Securities is required to be delivered
under the Act (including in circumstances where such requirement may be satisfied pursuant to Rule
172), any event occurs as a result of which the Prospectus as then supplemented would include any
untrue statement of a material fact or omit to state any material fact necessary to make the
statements therein in the light of the circumstances under which they were made not misleading, or
if it shall be necessary to amend the Registration Statement or supplement the Prospectus to comply
with the Act or the Exchange Act or the respective rules thereunder, the Company promptly will (1)
notify the Representatives of such event, (2) prepare and file with the Commission, subject to the
first sentence of paragraph (a) of this Section 5, an amendment or supplement which will correct
such statement or omission or effect such compliance and (3) supply any supplemented Prospectus to
you in such quantities as you may reasonably request. If at any time following issuance of an
Issuer Free Writing Prospectus there occurred or occurs an event or development as a result of
which such Issuer Free Writing Prospectus conflicted or would conflict with the information
contained in the Registration Statement (or any other registration statement relating to the
Securities) or the Time of Sale Prospectus or any preliminary prospectus or included or would include
an untrue statement of a material fact or omitted or would omit to state a material fact necessary
in order to make the statements therein, in the light of the circumstances prevailing at that
subsequent time, not misleading, the Company will promptly notify the Representatives and will
promptly amend or supplement, at its own expense, such Issuer Free Writing Prospectus to eliminate
or correct such conflict, untrue statement or omission.
9
(c) As soon as practicable, the Company will make generally available to its security holders
and to the Representatives an earnings statement or statements of the Company and its subsidiaries
which will satisfy the provisions of Section 11(a) of the Act and Rule 158 under the Act.
(d) The Company will furnish to the Representatives and counsel for the Underwriters, without
charge, copies of the Registration Statement (including exhibits thereto) and each amendment
thereto which shall become effective on or prior to the Closing Date and, so long as delivery of a
prospectus by an Underwriter or dealer may be required by the Act (including in circumstances where
such requirement may be satisfied pursuant to Rule 172), as many copies of any preliminary
prospectus and the Prospectus and any amendments thereof and supplements thereto as the
Representatives may reasonably request. The Company will pay or cause to be paid the following:
(i) the fees, disbursements and expenses of the Company’s counsel and accountants in connection
with the registration of the Securities under the Act and all other expenses in connection with the
preparation, printing and filing of the Registration Statement, any preliminary prospectus and the
Prospectus and amendments thereof and supplements thereto and the mailing and delivering of copies
thereof to the Underwriters and dealers; (ii) the expenses of printing all documents relating to
the offering (other than any agreement among Underwriters relating to the offering of the
Securities); (iii) all expenses in connection with the qualification of the Securities for offering
and sale under state securities laws or blue sky laws or the provincial securities laws of Canada,
and, if requested by the Representatives, preparing and printing a “Blue Sky Survey” or memorandum,
and any supplements thereto, advising the underwriters of such qualifications, registrations and
exemptions (as provided in Section 5(e) hereof, including the fees and disbursements of counsel for
the Underwriters in an amount not to exceed $10,000) as provided in Section 5(e) hereof; (iv) any
fees charged by securities rating agencies for rating the Securities; (v) the cost of preparing the
Securities; (vi) the fees and expenses of the Trustee and the fees and disbursements of counsel for
the Trustee in connection with this Agreement, the Indenture and the Securities; (vii) all
necessary issue, transfer and other stamp taxes in connection with the issuance and sale of the
Securities to the Underwriters; and (viii) all other costs and expenses incident to the performance
of its obligations hereunder which are not otherwise specifically provided for in this Section. It
is understood, however, that, except as provided in this Section, Section 7 and Section 8 hereof,
the Underwriters will pay all of their own costs and expenses, including the fees and disbursements
of their counsel, transfer taxes on resale of any of the Securities by them, and any advertising
expenses connected with any offers they may make.
(e) The Company will arrange for the qualification of the Securities for sale under the laws
of such jurisdictions as the Representatives may designate, will maintain such qualifications in
effect so long as required for the distribution of the Securities and will arrange for the
determination of the legality of the Securities for purchase by institutional investors; provided,
however, that the Company shall not be required to qualify to do business in any jurisdiction where
it is not now so qualified or to take any action which would subject it to general or unlimited
service of process in any jurisdiction where it is not now so subject.
10
(f) The Company will use its best efforts to list the Securities on the stock exchange, if
any, set forth in Schedule I hereto.
(g) The Company will not, without the prior written consent of the Representatives, offer,
sell, contract to sell, pledge, or otherwise dispose of, (or enter into any transaction which is
designed to, or might reasonably be expected to, result in the disposition (whether by actual
disposition or effective economic disposition due to cash settlement or otherwise) by the Company
or any entity affiliate of the Company or any person in privity with the Company or any entity
affiliate of the Company) directly or indirectly, including the filing (or participation in the
filing) of a registration statement with the Commission in respect of, or establish or increase a
put equivalent position or liquidate or decrease a call equivalent position within the meaning of
Section 16 of the Exchange Act, any debt securities issued or guaranteed by the Company that are
substantially similar to the Securities (other than the Securities and any debt securities that
mature within one year of their date of issue) or publicly announce an intention to effect any such
transaction, until the Business Day set forth on Schedule I hereto.
(h) The Company will not take, directly or indirectly, any action designed to or that would
constitute, under the Exchange Act or otherwise, stabilization or manipulation of the price of any
security of the Company to facilitate the sale or resale of the Securities.
(i) The Company will use the net proceeds received by it from the sale of the Securities in
the manner specified in the Time of Sale Prospectus and the Prospectus under “Use of Proceeds.”
(j) The Company represents and agrees that, unless it obtains the prior written consent of the
Representatives, and each Underwriter represents and agrees that, unless it obtains the prior
written consent of the Company and the Representatives, it has not made and will not make any offer
relating to the Securities that would constitute an “issuer free writing prospectus,” as defined in
Rule 433, or that would otherwise constitute a “free writing prospectus,” as defined in Rule 405,
required to be filed with the Commission or retained by the Company under Rule 433; provided,
however, that the prior written consent of the parties hereto shall be deemed to have been given in
respect of any free writing prospectus included in Schedule III hereto. Any such free writing
prospectus consented to by the Company and the Representatives is hereinafter referred to as a
“Permitted Free Writing Prospectus.” The Company represents that it has treated or agrees that it
will treat each Permitted Free Writing Prospectus as an “issuer free writing prospectus,” as
defined in Rule 433, and has complied and will comply with the requirements of Rule 433 applicable
to any Permitted Free Writing Prospectus, including timely filing with the Commission where
required, legending and record keeping.
6. Conditions to the Obligations of the Underwriters. The obligations of the
Underwriters to purchase the Securities shall be subject to the
accuracy in all material respects of the representations and
warranties on the part of the Company contained herein as of the date hereof, as of the date of the
effectiveness of any amendment to the Registration Statement filed prior to the Closing
11
Date (including the filing of any document incorporated therein by reference), as of the Time
of Sale and as of the Closing Date, to the accuracy in all material
respects of the statements of the Company made in any
certificates pursuant to the provisions hereof, to the performance in all material
respects by the Company of its
obligations hereunder and to the satisfaction of the following additional conditions in all material
respects:
(a) The Registration Statement has become effective and on the Closing Date no stop order
suspending the effectiveness of the Registration Statement shall have been issued under the Act or
proceedings therefor initiated or threatened by the Commission, no notice pursuant to Rule
401(g)(2) of the Regulations shall have been received by the Company and any request on the part of
the Commission for additional information shall have been complied with to the reasonable
satisfaction of counsel to the Underwriters. A prospectus containing the Rule 430B Information
shall have been filed with the Commission in the manner and within the time period required by Rule
424(b) without reliance on Rule 424(b)(8) (or a post-effective amendment providing such information
shall have been filed and become effective in accordance with the requirements of Rule 430B). The
Company shall have paid the required Commission filing fees relating to the Securities within the
time period required by Rule 456(1)(i) of the Regulations without regard to the proviso therein and
otherwise in accordance with Rules 456(b) and 457(r) of the 1933 Act Regulations and, if
applicable, shall have updated the “Calculation of Registration Fee” table in accordance with Rule
456(b)(1)(ii) either in a post-effective amendment to the Registration Statement or on the cover
page of a prospectus filed pursuant to Rule 424(b).
(b) The Company shall have furnished to the Representatives the opinion of counsel for the
Company, dated the Closing Date, with respect to the issuance and sale of the Notes, the Indenture, the Registration Statement, the Prospectus and other related matters as the Representatives may reasonably require.
(c) The Representatives shall have received from Xxxxx Xxxxx LLP, counsel for the
Underwriters, such opinion or opinions, dated the Closing Date, with respect to the issuance and
sale of the Securities, this Agreement, the Indenture, the Registration Statement, the Time of Sale
Prospectus, the Prospectus and other related matters as the Representatives may reasonably require,
and the Company shall have furnished to such counsel such documents
as they reasonably request for the purpose
of enabling them to pass upon such matters.
(d) The Company shall have furnished to the Representatives a certificate of the Company,
signed by the Chairman of the Board, the President or any Vice President and the principal
financial or accounting officer of the Company, dated the Closing Date, to the effect that the
signers of such certificate have carefully examined the Registration Statement, the Time of Sale
Prospectus, the Prospectus, any supplements to the Prospectus and this Agreement and that to the
best of their knowledge:
(i) the representations and warranties of the Company in this Agreement are true and
correct in all material respects on and as of the Closing Date with the same effect as if
made on the Closing Date and the Company has complied with all the agreements and satisfied
all the conditions on its part to be performed or satisfied at or prior to the Closing Date;
12
(ii) no stop order suspending the effectiveness of the Registration Statement, as
amended, has been issued and no proceedings for that purpose have been instituted or, to
their knowledge, threatened; and the Company has not received from the Commission any notice
pursuant to Rule 401(g)(2) under the Act objecting to use of the automatic shelf
registration statement form; and
(iii) since the date of the most recent financial statements included or incorporated
by reference in the Registration Statement, the Time of Sale Prospectus and the Prospectus
(exclusive of any supplement thereto), there has been no material adverse change, or any
development that would reasonably be expected to result in a material adverse change, in the
business, results of operations or financial condition of the Company and its subsidiaries,
considered as one entity, except as set forth or contemplated in the Registration Statement,
the Time of Sale Prospectus and the Prospectus (exclusive of any supplement thereto).
(e) On the date of this Agreement and on the Closing Date, the Company’s registered
independent public accountants shall have furnished to the Representatives, at the request of the
Company, letters, dated the respective dates of delivery thereof and addressed to the Underwriters,
in form and substance reasonably satisfactory to the Representatives, (1) confirming that they are
independent accountants with respect to the Company as required by the Securities Act and the rules
and regulations of the Commission thereunder and (2) with respect to the accounting, financing, or
statistical information (which is limited to accounting, financial or statistical information
derived from the general accounting records of the Company) contained in the Registration Statement
or Prospectus or incorporated by reference therein, and containing statements and information of
the type ordinarily included in accountants’ SAS 72 letters, as amended by SAS 6, “Comfort
Letters”, to underwriters with respect to the financial statements and certain financial
information contained in, or incorporated by reference into, the Registration Statement, and the
Time of Sale Prospectus and the Prospectus; provided that the letter delivered on the Closing Date
shall use a “cut-off” date no more than three business days prior to the Closing Date.
(f) Subsequent to the Time of Sale or, if earlier, the dates as of which information is given
in the Registration Statement (exclusive of any amendment thereof), the Time of Sale Prospectus
(exclusive of any amendment thereof or supplement thereto) and the Prospectus (exclusive of any
supplement thereto), there shall not have been (i) any change or decrease specified in the letter
or letters referred to in paragraph (e) of this Section 6 or (ii) any change, or any development
involving or affecting the business, results of operations or financial
condition of the Company and its subsidiaries, taken as a whole, whether or not arising from
transactions in the ordinary course of business, except as set forth in or contemplated in the Time
of Sale Prospectus (exclusive of any amendment thereof or supplement thereto) and the Prospectus
(exclusive of any supplement thereto) the effect of which, in any case referred to in clause (i) or
(ii) above, is, in the sole judgment of the Representatives, so material and adverse as to make it
impractical or inadvisable to proceed with the offering or delivery of the Securities as
contemplated by the Registration Statement
13
(exclusive of any amendment thereof), the Time of Sale Prospectus (exclusive of any amendment
thereof or supplement thereto) and the Prospectus (exclusive of any supplement thereto).
(g) Subsequent to the Time of Sale, there shall not have been any decrease in the rating of
any of the Company’s debt securities by any “nationally recognized statistical rating organization”
(as defined for purposes of Rule 436(g) under the Act).
(h) Prior to the Closing Date, the Company shall have furnished to the Representatives such
further information, certificates and documents as the Representatives may reasonably request.
If any of the conditions specified in this Section 6 shall not have been fulfilled in all
material respects when and as provided in this Agreement, or if any of the opinions and
certificates mentioned above or elsewhere in this Agreement shall not be in all material respects
reasonably satisfactory in form and substance to the Representatives and counsel for the
Underwriters, this Agreement and all obligations of the Underwriters hereunder may be canceled by
the Representatives at, or at any time prior to, the Closing Date. Notice of such cancellation
shall be given to the Company in writing or by telephone or telegraph confirmed in writing.
7. Reimbursement of Underwriters’ Expenses. If the sale of the Securities provided
for herein is not consummated because any condition to the obligations of the Underwriters set
forth in Section 6 hereof is not satisfied, because of any termination pursuant to Section
10(i)(with respect to a suspension in the trading of the Company’s common stock only) hereof or
because of any refusal, inability or failure on the part of the Company to perform any agreement
herein or comply with any provision hereof other than by reason of a default by any of the
Underwriters, the Company will reimburse the Underwriters severally through the Representatives on
demand for all out-of-pocket expenses (including reasonable fees and disbursements of counsel) that
shall have been reasonably incurred by them in connection with the proposed purchase and sale of
the Securities.
8. Indemnification and Contribution.
(a) The Company agrees to indemnify and hold harmless each Underwriter, its affiliates (as
such term is defined in Rule 501(b)), its selling agents and each person who controls any
Underwriter within the meaning of either the Act or the Exchange Act against any and all losses,
claims, damages or liabilities, joint or several, to which they or any of them may become subject
under the Act, the Exchange Act or other Federal or state statutory law or regulation, at common
law or otherwise, insofar as such losses, claims, damages or liabilities (or actions in respect
thereof) arise out of or are based upon any untrue statement or alleged untrue statement of a
material fact contained in the Registration Statement (any amendment thereof)(including the Rule
430B Information), or in the Time of Sale Prospectus, any preliminary prospectus, any Issuer Free
Writing Prospectus or the Prospectus, or in any amendment thereof
14
or supplement thereto, or arise out of or are based upon the omission or alleged omission to
state therein a material fact required to be stated therein or necessary to make the statements
therein not misleading, and agrees to reimburse each such indemnified party for any legal or other
expenses reasonably incurred by them in connection with investigating or defending any such loss,
claim, damage, liability or action; provided, however, that the Company will not be liable in any
such case to the extent that any such loss, claim, damage or liability arises out of or is based
upon any such untrue statement or alleged untrue statement or omission or alleged omission made
therein in reliance upon and in conformity with written information furnished to the Company by or
on behalf of any Underwriter through the Representatives specifically for use therein. This
indemnity agreement will be in addition to any liability which the Company may otherwise have.
(b) Each Underwriter severally agrees to indemnify and hold harmless the Company, each of its
directors, each of its officers who signs the Registration Statement, and each person who controls
the Company within the meaning of either the Act or the Exchange Act, to the same extent as the
foregoing indemnity from the Company to each Underwriter, but only with reference to written
information relating to such Underwriter furnished to the Company by or on behalf of such
Underwriter through the Representatives specifically for use in the preparation of the documents
referred to in the foregoing indemnity. This indemnity agreement will be in addition to any
liability which any Underwriter may otherwise have. The Company acknowledges that the following
statements set forth under the heading “Underwriting” in the Time of Sale Prospectus and the
Prospectus constitute the only information furnished in writing by or on behalf of the several
Underwriters for inclusion in any preliminary prospectus, the Time of Sale Prospectus or the
Prospectus: (i) the list of Underwriters and their respective participation in the sale of the
Securities, (ii) the sentences related to concessions and reallowances and (iii) the paragraph
related to stabilization and over-allotment transactions.
(c) Promptly after receipt by an indemnified party under this Section 8 of notice of the
commencement of any action, such indemnified party will, if a claim in respect thereof is to be
made against the indemnifying party under this Section 8, notify the indemnifying party in writing
of the commencement thereof; but the omission so to notify the indemnifying party will not relieve
it from any liability which it may have to any indemnified party otherwise than under this Section
8. In case any such action is brought against any indemnified party, and it notifies the
indemnifying party of the commencement thereof, the indemnifying party will be entitled to
participate therein and, to the extent that it may elect by written notice delivered to the
indemnified party promptly after receiving the aforesaid notice from such indemnified party, to
assume the defense thereof, with counsel satisfactory to such indemnified party; provided, however,
that if the defendants in any such action include both the indemnified party and the indemnifying
party and the indemnified party shall have reasonably concluded that there may be legal defenses
available to it and/or other indemnified parties which are different from or additional to those
available to the indemnifying party, the indemnified party or parties shall have the right to
select separate counsel to assert such legal defenses and to otherwise participate in the defense
of such action on behalf of such indemnified party or parties.
15
Upon receipt of notice from the indemnifying party to such indemnified party of its election
so to assume the defense of such action and approval by the indemnified party of counsel, the
indemnifying party will not be liable to such indemnified party under this Section 8 for any legal
or other expenses subsequently incurred by such indemnified party in connection with the defense
thereof unless (i) the indemnified party shall have employed separate counsel in connection with
the assertion of legal defenses in accordance with the proviso to the next preceding sentence (it
being understood, however, that the indemnifying party shall not be liable for the expenses of more
than one separate counsel, approved by the Representatives in the case of subparagraph (a),
representing the indemnified parties under subparagraph (a) who are parties to such action), (ii)
the indemnifying party shall not have employed counsel satisfactory to the indemnified party to
represent the indemnified party within a reasonable time after notice of commencement of the action
or (iii) the indemnifying party has authorized the employment of counsel for the indemnified party
at the expense of the indemnifying party; and except that, if clause (i) or (iii) is applicable,
such liability shall be only in respect of the counsel referred to in such clause (i) or (iii).
(d) The indemnifying party under this Section 8 shall not be liable for any settlement of any
proceeding effected without its written consent, but if settled with such consent or if there be a
final judgment for the plaintiff, the indemnifying party agrees to indemnify the indemnified party
against any loss, claim, damage, liability or expense by reason of such settlement or judgment.
Notwithstanding the foregoing sentence, if at any time an indemnified party shall have requested an
indemnifying party to reimburse the indemnified party for fees and expenses of counsel as
contemplated by Section 8(c) hereof, the indemnifying party agrees that it shall be liable for any
settlement of any proceeding effected without its written consent if (i) such settlement is entered
into more than 30 days after receipt by such indemnifying party of the aforesaid request and (ii)
such indemnifying party shall not have reimbursed the indemnified party in accordance with such
request prior to the date of such settlement. No indemnifying party shall, without the prior
written consent of the indemnified party, effect any settlement, compromise or consent to the entry
of judgment in any pending or threatened action, suit or proceeding in respect of which any
indemnified party is or could have been a party and indemnity was or could have been sought
hereunder by such indemnified party, unless such settlement, compromise or consent (i) includes an
unconditional release of such indemnified party from all liability on claims that are the subject
matter of such action, suit or proceeding and (ii) does not include a statement as to or an
admission of fault, culpability or a failure to act, by or on behalf of any indemnified party.
(e) In order to provide for just and equitable contribution in circumstances in which the
indemnification provided for in paragraph (a) of this Section 8 is due in accordance with its terms
but is for any reason held by a court to be unavailable from the Company on grounds of policy or
otherwise, the Company and the Underwriters shall contribute to the aggregate losses, claims,
damages and liabilities (including legal or other expenses reasonably incurred in connection with
investigating or defending same) to which the Company and one or more of the Underwriters may be
subject in such proportion so that the Underwriters are responsible for that portion represented by
the percentage that the underwriting discount bears to
16
the sum of such discount and the purchase price of the Securities specified in Schedule I
hereto and the Company is responsible for the balance; provided, however, that (y) in no case shall
any Underwriter (except as may be provided in any agreement among Underwriters relating to the
offering of the Securities) be responsible for any amount in excess of the underwriting discount
applicable to the Securities purchased by such Underwriter hereunder and (z) no person guilty of
fraudulent misrepresentation (within the meaning of Section 11(f) of the Act) shall be entitled to
contribution from any person who was not guilty of such fraudulent misrepresentation. For purposes
of this Section 8, each person who controls an Underwriter within the meaning of the Act shall have
the same rights to contribution as such Underwriter, and each director of the Company, each officer
of the Company who signs the Registration Statement, and each person who controls the Company
within the meaning of either the Act or the Exchange Act shall have the same rights to contribution
as the Company, subject in each case to clause (y) of this paragraph (e). Any party entitled to
contribution will, promptly after receipt of notice of the commencement of any action against such
party in respect of which a claim for contribution may be made against another party or parties
under this paragraph (e), notify such party or parties from whom contribution may be sought, but
the omission to so notify such party or parties shall not relieve the party or parties from whom
contribution may be sought from any other obligation it or they may have otherwise than under this
paragraph (e).
9. Default by an Underwriter. If any one or more Underwriters shall fail to purchase
and pay for any of the Securities agreed to be purchased by such Underwriter or Underwriters
hereunder and such failure to purchase shall constitute a default in the performance of its or
their obligations under this Agreement, the remaining Underwriters shall be obligated severally to
take up and pay for (in the respective proportions which the amount of Securities set forth
opposite their names in Schedule II hereto bear to the aggregate amount of Securities set forth
opposite the names of all the remaining Underwriters) the Securities which the defaulting
Underwriter or Underwriters agreed but failed to purchase; provided, however, that in the event
that the amount of Securities which the defaulting Underwriter or Underwriters agreed but failed to
purchase shall exceed 10% of the aggregate amount of Securities set forth in Schedule I hereto, the
remaining Underwriters shall have the right to purchase all, but shall not be under any obligation
to purchase any, of the Securities, and if such non-defaulting Underwriters do not purchase all the
Securities, this Agreement will terminate without liability to any non-defaulting Underwriter or
the Company. In the event of a default by any Underwriter as set forth in this Section 9, the
Closing Date shall be postponed for such period, not exceeding seven days, as the Representatives
shall determine in order that the required changes in the Registration Statement and the Prospectus
or in any other documents or arrangements may be effected. Nothing contained in this Agreement
shall relieve any defaulting Underwriter of its liability, if any, to the Company and to any
non-defaulting Underwriter for damages occasioned by its default hereunder.
10. Termination. This Agreement shall be subject to termination in the absolute
discretion of the Representatives, by notice given to the Company prior to delivery of and payment
for the Securities, if at any time prior to such time (i) trading in the Company’s Common Stock
shall have been suspended by the Commission or the New York Stock Exchange
17
or trading in securities generally on the New York Stock Exchange shall have been suspended or
limited or minimum prices shall have been established on such Exchange, (ii) a banking moratorium
shall have been declared either by Federal or New York State authorities or a material disruption
shall have occurred in securities settlement, payment or clearance services in the United States or
with respect to the Clearstream or Euroclear systems in Europe, or (iii) there shall have occurred
any outbreak or escalation of hostilities, declaration by the United States of a national emergency
or war, or other calamity or crisis the effect of which on the financial markets is such as to make
it, in the judgment of the Representatives, impracticable to proceed with the offering or delivery
of the Securities as contemplated by the Prospectus (exclusive of any supplement thereto).
11. Representations and Indemnities to Survive. The respective agreements,
representations, warranties, indemnities and other statements of the Company or its officers and of
the Underwriters set forth in or made pursuant to this Agreement will remain in full force and
effect, regardless of any investigation made by or on behalf of any Underwriter or the Company or
any of the officers, directors or controlling persons referred to in Section 8 hereof, and will
survive delivery of and payment for the Securities. The provisions of Sections 7 and 8 hereof
shall survive the termination or cancellation of this Agreement.
12. Notices. All communications hereunder will be in writing and effective only on
receipt, and, if sent to the Representatives, will be mailed, delivered or telegraphed and
confirmed to them at the address specified in Schedule I hereto; or, if sent to the Company, will
be mailed, delivered or telegraphed and confirmed to it at 00000 X.X. 000xx Xxxxxx,
Xxxxx, Xxxxxxx 00000, attention of the Treasurer.
13. Successors. This Agreement shall be binding upon and shall inure solely to the
benefit of the Underwriters, the Company and, to the extent provided in Sections 8 and 11 hereof,
the officers and directors of the Company and each person who controls the Company or an
Underwriter, and their respective heirs, executors, administrators, successors and assigns, and no
other person shall acquire or have any right under or by virtue of this Agreement. No purchaser of
any of the Securities from an Underwriter shall be deemed a successor or assign by reason merely of
such purchase.
14. Applicable Law. This Agreement will be governed by and construed in accordance
with the laws of the State of New York applicable to contracts made and to be performed within the
State of New York.
15. Counterparts. This Agreement may be executed by any one or more of the parties
hereto in any number of counterparts, each of which shall be deemed to be an original, but all such
counterparts shall together constitute one and the same instrument.
16. Headings. The section headings used herein are for convenience only and shall not
affect the construction hereof.
18
17. Definitions. The terms which follow, when used in this Agreement, shall have the
meanings indicated.
“Act” shall mean the Securities Act of 1933, as amended and the rules and regulations of the
Commission promulgated thereunder.
“Business Day” shall mean any day other than a Saturday, a Sunday or a legal holiday or a day
on which banking institutions or trust companies are authorized or obligated by law to close in New
York City.
“Commission” shall mean the Securities and Exchange Commission.
“Exchange Act” shall mean the Securities Exchange Act of 1934, as amended, and the rules and
regulations of the Commission promulgated thereunder.
“Issuer Free Writing Prospectus” means any “issuer free writing prospectus,” as defined in
Rule 433, relating to the Securities that (i) is required to be filed with the Commission by the
Company, or (ii) is exempt from filing pursuant to Rule 433(d)(5)(i) because it contains a
description of the Securities or of the offering that does not reflect the final terms, in each
case in the form filed or required to be filed with the Commission or, if not required to be filed,
in the form retained in the Company’s records pursuant to Rule 433(g).
“Issuer General Use Free Writing Prospectus” means any Issuer Free Writing Prospectus that is
intended for general distribution to prospective investors, as evidenced by its being specified in
Schedule III hereto.
“Investment Company Act” means the Investment Company Act of 1940, as amended.
“Regulations” shall mean the rules and regulations of the Commission.
“Rule 163,” “Rule 164,” “Rule 401,” “Rule 405,” “Rule 415”, “Rule 424”, “Rule 430B,” “Rule
433,” “Rule 462” and “Rule 501” refer to such rules under the Act.
“Rule 430B Information” shall mean information included in the Prospectus that was omitted
from the Registration Statement at the time it became effective but that is deemed to be part of
and included in the Registration Statement pursuant to Rule 430B.
“Time of Sale” means •:00 p.m. (Eastern time) on •, • or such other time as agreed by the
Company and the Representatives.
“Time of Sale Prospectus” shall mean Base Prospectus, the Preliminary Prospectus Supplement,
the issuer free writing prospectuses as defined in Rule 433 under the Act (each, an “Issuer Free
Writing Prospectus”), if any, identified in Schedule III hereto and (iii) any other free writing
prospectus that the parties hereto shall hereafter expressly agree in writing to treat as part of
the Time of Sale Prospectus, each as of the Time of Sale.
19
“Trust Indenture Act” shall mean the Trust Indenture Act of 1939, as amended and the rules and
regulations of the Commission promulgated thereunder.
18. No Fiduciary Duty. The Company hereby acknowledges that (a) the purchase and sale
of the Securities pursuant to this Agreement is an arm’s-length commercial transaction between the
Company, on the one hand, and the Underwriters and any affiliate through which it may be acting, on
the other, (b) the Underwriters are not acting as fiduciaries of the Company and (c) the Company’s
engagement of the Underwriters in connection with the offering and the process leading up to the
offering is as independent contractors and not in any other capacity. Furthermore, the Company
agrees that it is solely responsible for making its own judgments in connection with the offering
(irrespective of whether any of the Representatives has advised or is currently advising the
Company on related or other matters). The Company agrees that it will not claim that the
Underwriters have rendered advisory services of any nature or respect, or owe an agency, fiduciary
or similar duty to the Company, in connection with such transaction or the process leading thereto.
This Agreement supersedes all prior agreements and understandings (whether written or oral)
between the Company and the several Underwriters, or any of them, with respect to the subject
matter hereof. The Company hereby waives and releases, to the fullest extent permitted by law, any
claims that the Company may have against the several Underwriters with respect to any breach or
alleged breach of agency or fiduciary duty.
If the foregoing is in accordance with your understanding of our agreement, please sign and
return to us the enclosed duplicate hereof, whereupon this letter and your acceptance shall
represent a binding agreement among the Company and the several Underwriters.
20
If the foregoing is in accordance with your understanding of our agreement, please sign and
return to us the enclosed duplicate hereof, whereupon this letter and your acceptance shall
represent a binding agreement among the Company and the several Underwriters.
Very truly yours, RYDER SYSTEM, INC. |
||||
By: | ||||
Name: Title: |
||||
The foregoing Agreement is hereby confirmed
and accepted as of the date specified in Schedule I hereto.
and accepted as of the date specified in Schedule I hereto.
[NAME OF REPRESENTATIVES]
By: |
||||
Title: | ||||
For themselves and the other several Underwriters, if any, named in Schedule II to the foregoing Agreement. |
21
SCHEDULE I
Underwriting Agreement dated
Representative(s):
Closing date and time:
Description of Securities:
Title:
Specified Currency: U.S. dollars
Aggregate principal amount: $
Stated maturity date:
Purchase price (include accrued interest or amortization, if any): %
Sinking fund provisions:
Redemption provisions:
Change of Control Provisions:
Other provisions:
Interest Payment Dates:
Record Dates:
Method of Payment: Same-day funds
Stock exchange listing, if any: None
Last Day of Blackout Period Pursuant to Section 5(g): First Business Day after the Closing Date
Additional procedures to be performed by {Accountants], if any: None
SCHEDULE II
Principal Amount of | ||||
Underwriter | Notes | |||
Total. |
$ | |||
Schedule III
Issuer General Use Free Writing Prospectus
Final Term Sheet
Exhibit A
Form of Final Term Sheet
Filed Pursuant to Rule 433
Registration No. 333- •
Dated •
Registration No. 333- •
Dated •
$l
RYDER SYSTEM, INC.
$• •% [Debentures][Notes] due •
RYDER SYSTEM, INC.
$• •% [Debentures][Notes] due •
Final Term Sheet
Issuer:
|
Ryder System, Inc. | |
Ratings (Xxxxx’x/S&P/Fitch): |
||
Format:
|
SEC Registered | |
Ranking:
|
Senior Unsecured | |
Size:
|
$ | |
Trade Date: |
||
Settlement Date: |
||
Final Maturity: |
||
Interest Payment Dates: |
||
First Interest Payment Date: |
||
Pricing Benchmark: |
||
UST Spot (PX/Yield): |
||
Spread to Benchmark: |
||
Yield to Maturity: |
||
Coupon: |
||
Price to Public: |
||
Day Count: |
||
Optional Redemption: |
||
Bookrunners: |
||
Co-managers: |
||
CUSIP: |
||
Exchange Listing:
|
None |
The issuer has filed registration statements (including prospectuses) with the SEC for the
offering to which this communication relates. Before you invest, you should read the prospectuses
in those registration statements and other documents the issuer has filed with the SEC for more
complete information about the issuer and this offering. You may get these documents for free by
visiting XXXXX on the SEC Web site at xxx.xxx.xxx. Alternatively, the issuer, any underwriter or
any dealer participating in the offering will arrange to send you the prospectus if you request it
by calling toll-free or e-mailing: .
25